|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19,750.00 KRW | -15.60% |
|
-10.23% | -65.59% |
| 07-23 | Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell | MT |
| 12-21 | IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index | CI |
Company Valuation: IntoCell, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 |
|---|---|
| Market Cap 1 | 861,052 |
| Change | - |
| Enterprise Value (EV) 1 | 840,466 |
| Change | - |
| P/E | -77.1x |
| PBR | 34.8x |
| PEG | 48.66x |
| Capitalization / Revenue | 374,513,177x |
| EV / Revenue | - |
| EV / EBITDA | -88.2x |
| EV / EBIT | -81.6x |
| EV / FCF | -132x |
| FCF Yield | -0.76% |
| Dividend per Share 2 | - |
| Rate of return | - |
| EPS 2 | -744 |
| Distribution rate | - |
| Net sales | 2,299 |
| EBITDA 1 | -9,526 |
| EBIT 1 | -10,300 |
| Net income 1 | -10,603 |
| Net Debt 1 | -20,586 |
| Reference price 2 | 57,400.00 |
| Nbr of stocks (in thousands) | 15,001 |
| Announcement Date | 3/1/26 |
1KRW in Million2KRW
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 203M | |
| 32.25x | 5.76x | 17.3x | 1.02% | 46.86B | |
| -23.62x | 354.58x | -21.66x | -.--% | 40.23B | |
| 48.91x | 4.94x | 31.87x | -.--% | 36.23B | |
| 25.32x | 2.8x | 12.1x | -.--% | 34.72B | |
| 27.42x | 8.04x | 20.17x | 0.41% | 27.89B | |
| 34.31x | 5.61x | 25.58x | -.--% | 16.79B | |
| 22.12x | 1.95x | 8.48x | 1.19% | 13.12B | |
| 23.43x | 1.87x | 11.34x | -.--% | 12.7B | |
| Average | 23.77x | 48.19x | 13.15x | 0.33% | 25.42B | |
| Weighted average by Cap. | 22.49x | 66.41x | 12.08x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A287840 Stock
- Valuation IntoCell, Inc.
Select your edition
All financial news and data tailored to specific country editions
